Get started
Author

Minjie Feng

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
2020 · Danny Rischin, Marta Gil-Martin, et al. · Gynecologic Oncology · 79
PDF
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
2019 · Kyriakos P. Papadopoulos, Melissa L. Johnson, et al. · Clinical Cancer Research · 68
Non-invasive Blood Pressure Measurement in Mice
2009 · Minjie Feng, Keith DiPetrillo · Methods in molecular biology · 58
Genome-Wide Association Mapping of Quantitative Traits in Outbred Mice
2012 · Weidong Zhang, Ron Korstanje, et al. · G3 Genes Genomes Genetics · 50
PDF
Genetic Analysis of Blood Pressure in 8 Mouse Intercross Populations
2009 · Minjie Feng, Marion E. Deerhake, et al. · Hypertension · 36
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2021 · Hani Babiker, Irene Brana, et al. · The Oncologist · 27
PDF
Genetic analysis of albuminuria in collaborative cross and multiple mouse intercross populations
2012 · Jill Thaisz, Shirng-Wern Tsaih, et al. · American Journal of Physiology-Renal Physiology · 21
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.
2023 · Danny Nguyen, Elaine Shum, et al. · Journal of Clinical Oncology · 11
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.
2018 · Krishnansu Sujata Tewari, Ignace Vergote, et al. · Journal of Clinical Oncology · 6
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.
2019 · Victor Moreno, Emiliano Calvo, et al. · Journal of Clinical Oncology · 5
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.
2018 · Victor Moreno Garcia, Emiliano Calvo, et al. · Journal of Clinical Oncology · 5
Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
2025 · Ben C. Creelan, Scott N. Gettinger, et al. · Journal of Clinical Oncology · 2
Supplementary Data from First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
2023 · Kyriakos P. Papadopoulos, Melissa L. Johnson, et al.
Data from First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
2023 · Kyriakos P. Papadopoulos, Melissa L. Johnson, et al.
Data from First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
2023 · Kyriakos P. Papadopoulos, Melissa L. Johnson, et al.
Control aspects of left ventricular wall thickness in pressure overload left ventricular hypertrophy
2003 · Minjie Feng, G.M. Drzewiecki, et al. · IEEE Annual Northeast Bioengineering Conference (NEBEC)
Progression of left ventricular wall thickness during pressure-overload left ventricular hypertrophy
2002 · Minjie Feng, J.K.-J. Li, et al. · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
Works count: 17
Citation count: 368
H-index: 8
I10-index: 8
Year
Topic
Type